Table 2.
Total (n = 456) | No progression (n = 205) | Poor prognoses (n = 251) | p value | |
---|---|---|---|---|
Treatment | ||||
Antivirala | 437 (95.83%) | 193 (94.14%) | 244 (97.21%) | 0.103 |
Antibioticb | 369 (80.92%) | 173 (84.39%) | 196 (78.08%) | 0.088 |
Glucocorticoids | 226 (49.56%) | 70 (34.14%) | 156 (62.15%) | <0.001 |
Intravenous immunoglobulin | 145 (31.79%) | 54 (26.31%) | 91 (36.25%) | 0.024 |
Outcomes | ||||
Time from illness onset to admission, days | 7 (4.25–14) | 8 (4–14) | 7 (5–11) | 0.135 |
Severe progression | — | — | 155 (61.75%) | |
Critical progression | — | — | 50 (19.92%) | |
Death progression | — | — | 46 (18.33%) |
Data are n (%). Normal distributed data are mean ± SD and non-normal distributed data are median (IQR).
Antiviral treatments included ribavirin, arbidol and lopinavir/ritonavir.
Antibiotic treatments included cephalosporins and quinolones.